TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7865199

Group type: EXPERIMENTAL
Intervention: Mixed-age classes
Number of subjects: 48

Group type: COMPARATOR
Intervention: Same-age classes
Number of subjects: 48
Study: 2599125

Group type: EXPERIMENTAL
Intervention: Hickman‐Broviac (HB) catheter
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Port‐a‐Cath (PAC)
Number of subjects: 447
Study: 1205398

Group type: EXPERIMENTAL
Intervention: Light stimulus provided by a 250 watt bulb lit for 20 minutes
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Randomized sequence of light stimulus (on/on/off or off/off/on)
Number of subjects: 143
Study: 27629797

Group type: EXPERIMENTAL
Intervention: Psychosocial variables (self-efficacy, treatment expectation, social support)
Number of subjects: 200
Study: 25261009

Group type: EXPERIMENTAL
Intervention: Handouts with photographs of clinicians
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Handouts with names and roles of clinicians
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 186
Study: 23341160

Group type: COMPARATOR
Intervention: Intermittent infusion of ß‐lactam antibiotics (meropenem, piperacillin‐tazobactam, cefepime) over 30 minutes
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Prolonged infusion of ß‐lactam antibiotics (meropenem, piperacillin‐tazobactam, cefepime) over 3 hours
Number of subjects: 503

Group type: COMPARATOR
Intervention: Intermittent infusion of ß‐lactam antibiotics
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Prolonged infusion of ß‐lactam antibiotics
Number of subjects: 503

Group type: COMPARATOR
Intervention: Intermittent infusion group
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Prolonged infusion group
Number of subjects: 503
Study: 22039325

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Heater probe coagulation (HPC)
Number of subjects: 85
Study: 19444515

Group type: EXPERIMENTAL
Intervention: Prolonged catheter drainage
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 58
Study: 17076053

Group type: EXPERIMENTAL
Intervention: 12-week group intervention targeting improvement of self-concept and overall quality of life
Number of subjects: 52

Group type: COMPARATOR
Intervention: High quality treatment as usual (control group)
Number of subjects: 52
Study: 15017618

Group type: EXPERIMENTAL
Intervention: rifaximin
Number of subjects: 0
Study: 11730649

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Travoprost 0.0015%
Number of subjects: 426

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 426
Study: 9356060

Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (contralateral legs)
Number of subjects: 0
Study: 9114913

Group type: EXPERIMENTAL
Intervention: Once daily dosing (o.d.) of modified-release carbamazepine (CBZ-MR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Twice daily dosing (b.d.) of modified-release carbamazepine (CBZ-MR)
Number of subjects: 14
Study: 3303997

Group type: EXPERIMENTAL
Intervention: Cladosporium allergen preparation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Histamine placebo
Number of subjects: 11
Study: 31838029

Group type: EXPERIMENTAL
Intervention: Oral metolazone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IV chlorothiazide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metolazone
Number of subjects: 60
Study: 31347763

Group type: EXPERIMENTAL
Intervention: Paced breathing alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternating upper extremity muscle contractions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paced breathing synchronized with alternating contractions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral control task
Number of subjects: 0
Study: 28207912

Group type: COMPARATOR
Intervention: OCD participants during habituation
Number of subjects: 80

Group type: COMPARATOR
Intervention: OCD participants during acquisition
Number of subjects: 80

Group type: COMPARATOR
Intervention: OCD participants during extinction
Number of subjects: 80

Group type: COMPARATOR
Intervention: HC participants during acquisition
Number of subjects: 80

Group type: COMPARATOR
Intervention: HC participants during extinction
Number of subjects: 80

Group type: COMPARATOR
Intervention: OCD participants overall
Number of subjects: 80
Study: 26177035

Group type: EXPERIMENTAL
Intervention: SPECT/CT scan of the lumbar spine prior to diagnostic infiltration of the medial branches
Number of subjects: 29

Group type: COMPARATOR
Intervention: Diagnostic infiltrations with local anesthetics
Number of subjects: 29
Study: 23382120

Group type: EXPERIMENTAL
Intervention: Hybrid problem-based learning (hybrid-PBL)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Lecture-based learning (LBL)
Number of subjects: 205
Study: 21435540

Group type: EXPERIMENTAL
Intervention: Implant-anchored treatment (IA group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional edgewise treatment (non-IA group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study: 19308298

Group type: EXPERIMENTAL
Intervention: Group-based stress management intervention (3 months)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 102
Study: 17112361

Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (PCA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCA plus continuous femoral nerve block
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCA plus continuous posterior lumbar plexus block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 14586494

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 8
Study: 11924697

Group type: EXPERIMENTAL
Intervention: Case-patients seeking help from any consultant
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Case-patients seeking help from a professional consultant
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Case-patients discussing suicide with any consultant
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Case-patients discussing suicide with professionals
Number of subjects: 153
Study: 9135487

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy to the breast
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: > or = 10 lymph nodes found in the axillary specimen
Number of subjects: 381

Group type: COMPARATOR
Intervention: < 10 lymph nodes found in the axillary specimen
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Postoperative wound complications
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Employed patients
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Patients < 65 years of age
Number of subjects: 381

Group type: COMPARATOR
Intervention: Retired patients
Number of subjects: 381

Group type: COMPARATOR
Intervention: Patients > = 65 years of age
Number of subjects: 381
Study: 8093742

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 3522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3522
Study: 3039431

Group type: EXPERIMENTAL
Intervention: adriamycin + VM 26 + 5-Fluorouracil (5-FU)
Number of subjects: 47

Group type: COMPARATOR
Intervention: mAMSA + VM 26 + 5-Fluorouracil (5-FU)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 47
Study: 29672097

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Fatigue catastrophizing
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Positive affect
Number of subjects: 163
Study: 26754181

Group type: EXPERIMENTAL
Intervention: SRP + DL
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study: 24163282

Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Pooled Sumatriptan (25 mg and 50 mg)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 22190398

Group type: EXPERIMENTAL
Intervention: rPA vaccine (formalin treated, alum adsorbed, or both)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: formalin‐only‐treated rPA
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: alum‐adsorbed rPA
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: two dosages of rPA
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: rPA vaccine
Number of subjects: 186

Group type: COMPARATOR
Intervention: AVA (licensed vaccine)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: anti‐rPA measured by ELISA
Number of subjects: 186
Study: 21090159

Group type: EXPERIMENTAL
Intervention: A-mode ultrasound
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sinus computed tomography (CT)
Number of subjects: 140
Study: 18534975

Group type: EXPERIMENTAL
Intervention: Sildenafil (0.7 mg/kg body weight, single oral dose)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 27
Study: 17135987

Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and cognitive-behavioral therapy (COMB)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 12761722

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pouch surveillance guidelines
Number of subjects: 0
Study: 11011281

Group type: EXPERIMENTAL
Intervention: 0.1% estradiol gel (Gel A)
Number of subjects: 48
Study: 8627394

Group type: EXPERIMENTAL
Intervention: Enhanced professional practice model
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 5
Study: 1597214

Group type: EXPERIMENTAL
Intervention: Diving (D, 45 s)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cold Pressor Test (CPT, 2 min)
Number of subjects: 22
Study: 6374193

Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL) administered 3 times a day at a daily dosage of 750 mg for 3 to 5 days.
Number of subjects: 243

Group type: COMPARATOR
Intervention: Cephalexin (CEX) administered 4 times a day at a daily dosage of 1,000 mg for 3 to 5 days.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Cephalexin (CEX)
Number of subjects: 243
Study: 31521136

Group type: EXPERIMENTAL
Intervention: SMS intervention to support home exercise adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: No SMS intervention
Number of subjects: 0
Study: 29335742

Group type: EXPERIMENTAL
Intervention: Water-in-oil emollient containing licochalcone A, omega-6-fatty acids, ceramide 3, and glycerol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 26301519

Group type: EXPERIMENTAL
Intervention: AOT plus BCI-FES
Number of subjects: 30
Study: 24338076

Group type: EXPERIMENTAL
Intervention: Stage-based, tailored policy advocacy assistance
Number of subjects: 186

Group type: COMPARATOR
Intervention: No assistance
Number of subjects: 186
Study: 22301087

Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral therapy (CBT) for depression and substance use
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 73
Study: 19852872

Group type: EXPERIMENTAL
Intervention: (6S)-5-methyltetrahydrofolic acid
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 163

Group type: COMPARATOR
Intervention: Folate-rich foods
Number of subjects: 163
Study: 18006623

Group type: EXPERIMENTAL
Intervention: Candesartan plus spironolactone (group A; n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Candesartan alone (group B; n = 25)
Number of subjects: 50
Study: 16108771

Group type: COMPARATOR
Intervention: Standard doses of Peginterferon alpha‐2b + ribavirin (Group A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Higher doses of Peginterferon alpha‐2b administered twice weekly + ribavirin (Group B)
Number of subjects: 65
Study: 12610185

Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Perceived high levels of ageism
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Perceived high levels of racism
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Processes of care
Number of subjects: 1812
Study: 10547511

Group type: EXPERIMENTAL
Intervention: Round arch wires
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rectangular arch wires
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study: 9324785

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 205
Study: 1822761

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 6239753

Group type: EXPERIMENTAL
Intervention: 200 mg meptazinol 4-times daily for up to 3 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: 250 mg diflunisal 4-times daily for up to 3 weeks
Number of subjects: 70
Study: 31021886

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intravenous dexamethasone before incision
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 150 mg oral pregabalin 1 hour before surgery
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of 0.2 mg/kg intravenous dexamethasone and 150 mg oral pregabalin
Number of subjects: 160

Group type: COMPARATOR
Intervention: None of the above (control)
Number of subjects: 160
Study: 27568165

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (n=818) consisting of aerobic, resistance, and flexibility exercises performed both center-based (2 times/week) and home-based (3-4 times/week) sessions
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education program (n=817) consisting of weekly to monthly workshops covering relevant health information
Number of subjects: 1635
Study: 26763225

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitors (ICM)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Control
Number of subjects: 441
Study: 24509399

Group type: EXPERIMENTAL
Intervention: AAI-guided anaesthesia
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (clinical signs only)
Number of subjects: 450
Study: 22488770

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (Gd‐BOPTA) 0.15 mmol/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (Gd‐DTPA) 0.15 mmol/kg
Number of subjects: 20
Study: 19175935

Group type: EXPERIMENTAL
Intervention: Group I - progressive resistance exercises (PRE) + functionally-oriented exercises (FOE) + nutritional supplementation (NS)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Group II - PRE + FOE + placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Group III - standard exercises (SE) + FOE + NS
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Group IV - SE + FOE + placebo
Number of subjects: 91
Study: 17289886

Group type: EXPERIMENTAL
Intervention: CellSearch system (Veridex, Warren, NJ)
Number of subjects: 92
Study: 16135479

Group type: EXPERIMENTAL
Intervention: 66 Gy in 33 fractions over 45 days (long arm)
Number of subjects: 936

Group type: COMPARATOR
Intervention: 52.5 Gy in 20 fractions over 28 days (short arm)
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 936
Study: 11359222

Group type: EXPERIMENTAL
Intervention: Electroporation (EP) with 4%, 10%, or 20% lidocaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electroporation (EP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electroincorporation (EI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Iontophoresis (IP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 10
Study: 9274835

Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) in conjunction with ciclosporin and steroids
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ciclosporin and steroids
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Number of subjects: 3
Study: 7876400

Group type: EXPERIMENTAL
Intervention: i.v. torsemide
Number of subjects: 19

Group type: COMPARATOR
Intervention: i.v. furosemide
Number of subjects: 19
Study: 3724121

Group type: EXPERIMENTAL
Intervention: Monosyllabic adaptive speech test (MAST) procedures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Different randomization of the same speech stimuli presented at a constant level, equal to their MAST threshold
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MAST threshold procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MAST thresholds
Number of subjects: 60
Study: 29291623

Group type: EXPERIMENTAL
Intervention: Propensity Score Analysis (PSA) based on pretest and demographic covariates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized study of a pre-K math curriculum
Number of subjects: 0
Study: 26527239

Group type: EXPERIMENTAL
Intervention: Aggressive thrombus aspiration (TA) using 7F devices or a catheter/artery ratio >0.6
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conservative thrombus aspiration (TA) using 6F devices or a catheter/artery ratio ≤0.6
Number of subjects: 76
Study: 24886488

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily in addition to routine care
Number of subjects: 2616

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 2616
Study: 23570952

Group type: EXPERIMENTAL
Intervention: Various antidepressants and augmentation strategies including extended-release venlafaxine, mitazapine, paroxetine, risperidone, sodium valproate, buspirone, trazodone, thyroid hormone augmenting to paroxetine
Number of subjects: 375
Study: 21345603

Group type: EXPERIMENTAL
Intervention: Rearing system 1
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rearing system 2
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rearing system 3
Number of subjects: 61

Group type: COMPARATOR
Intervention: All rearing systems
Number of subjects: 61
Study: 18805603

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin‐BPO 2.5%)
Number of subjects: 2813

Group type: COMPARATOR
Intervention: Individual active ingredients
Number of subjects: 2813

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2813
Study: 17121727

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine combined with fentanyl (KF group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Exclusive use of fentanyl (FT group)
Number of subjects: 80
Study: 12857557

Group type: EXPERIMENTAL
Intervention: Factor V Leiden mutation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Factor II A20210 mutation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pre-eclampsia (PE)
Number of subjects: 50
Study: 11143865

Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 0
Study: 9433391

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once a day for 5 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1531972

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Clodronate
Number of subjects: 82
Study: 6806060

Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine in the evening (group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine both morning and evening (group B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No treatment (group C)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups A and B (treated)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 66
Study: 30523032

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) with exendin(9-39) infusion
Number of subjects: 34
Study: 29702716

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control
Number of subjects: 164
Study: 26551044

Group type: EXPERIMENTAL
Intervention: Er:YAG AFL‐PDT (single session, n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: MAL‐PDT (two sessions, 7 days apart, n = 19)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Er:YAG AFL‐PDT
Number of subjects: 39

Group type: COMPARATOR
Intervention: MAL‐PDT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Er:YAG AFL‐PDT and MAL‐PDT
Number of subjects: 39
Study: 24315907

Group type: EXPERIMENTAL
Intervention: 5 mg morphine intravenously
Number of subjects: 24
Study: 21390540

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (Project EXPLORE), details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-Latino MSM), details on intervention not specified.
Number of subjects: 0
Study: 19709634

Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone administration
Number of subjects: 0
Study: 17482439

Group type: EXPERIMENTAL
Intervention: Fine needle aspiration coupled with real-time PCR
Number of subjects: 21
Study: 16880099

Group type: EXPERIMENTAL
Intervention: ccTGA
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study: 14691993

Group type: EXPERIMENTAL
Intervention: Audiotaped recording of the consultation
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Non-technical letter
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 117